SAN FRANCISCO and GENEVA, Oct. 16, 2014 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (AMBS), a biotechnology company focused on the development of diagnostics and therapeutics for Alzheimer's disease, Parkinson's disease and ophthalmological disorders, announced that it has applied to the US Food & Drug Administration for Orphan Drug Designation for MANF (mesencephalic-astrocyte-derived neurotrophic factor) in retinitis pigmentosa (RP). MANF was discovered utilizing Amarantus' proprietary PhenoGuard Protein Discovery Engine; all intellectual property is owned by the company.

Interesting that they "pumped " PhenoGuard in the opening statement in yesterday's PR.

I think that we will be hearing more about PhenoGuard shortly-could be a sleeping giant.

$AMBS$